ESTRO 2025 - Abstract Book

S254

Brachytherapy - Gynaecology

ESTRO 2025

Three patients with small T1 tumours received IGABT alone, while 77 (96%) patients underwent EBRT and IGABT. EBRT doses ranged from 41.4–50.4Gy (1.8–2.0 Gy /fraction) for the elective target volume, with optional boosts for enlarged lymph nodes. CCHT was administered to 61 patients (76%), with 54 (67%) receiving cisplatin and 7 (9%) receiving alternative regimens due to comorbidities. Eighteen patients (23%) did not receive chemotherapy, and 1 patient (1%) underwent neoadjuvant cisplatin chemotherapy. IGABT was administered as PDR-BT in 54 patients, HDR-BT in 20 patients, and both in 6 patients. Treatment planning used MRI in 71 patients, CT in 6 patients, and X-ray in 3 patients (frail patients with complete remission after EBRT; HDR). The median D90 to the CTV-HR was 84Gy EQD2 10 for patients receiving both EBRT and brachytherapy. The median D2 cm3 doses for the organs at risk (OARs) were as follows: bladder 67.4Gy EQD2 3 , rectum 64.7Gy EQD2 3 , sigmoid 53.45Gy EQD2 3 , and urethra 75.1Gy EQD2 3 . Median follow-up for survival was 63 months and 39 months for disease control. OS was 72 % at 5 years. There were 8 local, 5 regional, and 9 distant recurrences (Figure 1).